Maravai LifeSciences Holdings, Inc. MAR.F Stock
Maravai LifeSciences Holdings, Inc. Price Chart
Maravai LifeSciences Holdings, Inc. MAR.F Financial and Trading Overview
Maravai LifeSciences Holdings, Inc. stock price | 8.2 EUR |
Previous Close | 9.6 EUR |
Open | 9.5 EUR |
Bid | 9.75 EUR x N/A |
Ask | 10 EUR x N/A |
Day's Range | 9.5 - 9.75 EUR |
52 Week Range | 8.9 - 26.92 EUR |
Volume | 170 EUR |
Avg. Volume | 14 EUR |
Market Cap | 2.46B EUR |
Beta (5Y Monthly) | -0.256589 |
PE Ratio (TTM) | 18.396227 |
EPS (TTM) | -0.91 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 59.38 EUR |
MAR.F Valuation Measures
Enterprise Value | 1.68B EUR |
Trailing P/E | 18.396227 |
Forward P/E | 7.3863635 |
PEG Ratio (5 yr expected) | -10.81 |
Price/Sales (ttm) | 4.5169272 |
Price/Book (mrq) | 2.4702306 |
Enterprise Value/Revenue | 3.09 |
Enterprise Value/EBITDA | 6.686 |
Trading Information
Maravai LifeSciences Holdings, Inc. Stock Price History
Beta (5Y Monthly) | -0.256589 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 26.92 EUR |
52 Week Low | 8.9 EUR |
50-Day Moving Average | 10.94 EUR |
200-Day Moving Average | 12.55 EUR |
MAR.F Share Statistics
Avg. Volume (3 month) | 14 EUR |
Avg. Daily Volume (10-Days) | 17 EUR |
Shares Outstanding | 131.92M |
Float | 109.9M |
Short Ratio | N/A |
% Held by Insiders | 0.59% |
% Held by Institutions | 99.03% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 13.88% |
Operating Margin (ttm) | 39.81% |
Gross Margin | 69.37% |
EBITDA Margin | 46.21% |
Management Effectiveness
Return on Assets (ttm) | 6.10% |
Return on Equity (ttm) | 20.79% |
Income Statement
Revenue (ttm) | 543.92M EUR |
Revenue Per Share (ttm) | 4.13 EUR |
Quarterly Revenue Growth (yoy) | -71.59% |
Gross Profit (ttm) | 714.04M EUR |
EBITDA | 251.37M EUR |
Net Income Avi to Common (ttm) | 75.5M EUR |
Diluted EPS (ttm) | 0.53 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 580.18M EUR |
Total Cash Per Share (mrq) | 4.4 EUR |
Total Debt (mrq) | 617.27M EUR |
Total Debt/Equity (mrq) | 68.77 EUR |
Current Ratio (mrq) | 9.334 |
Book Value Per Share (mrq) | 3.947 |
Cash Flow Statement
Operating Cash Flow (ttm) | 313.66M EUR |
Levered Free Cash Flow (ttm) | 185.57M EUR |
Profile of Maravai LifeSciences Holdings, Inc.
Country | Germany |
State | CA |
City | San Diego |
Address | 10770 Wateridge Circle |
ZIP | 92121 |
Phone | 858 546 0004 |
Website | https://www.maravai.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 660 |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Q&A For Maravai LifeSciences Holdings, Inc. Stock
What is a current MAR.F stock price?
Maravai LifeSciences Holdings, Inc. MAR.F stock price today per share is 8.2 EUR.
How to purchase Maravai LifeSciences Holdings, Inc. stock?
You can buy MAR.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Maravai LifeSciences Holdings, Inc.?
The stock symbol or ticker of Maravai LifeSciences Holdings, Inc. is MAR.F.
Which industry does the Maravai LifeSciences Holdings, Inc. company belong to?
The Maravai LifeSciences Holdings, Inc. industry is Biotechnology.
How many shares does Maravai LifeSciences Holdings, Inc. have in circulation?
The max supply of Maravai LifeSciences Holdings, Inc. shares is 253.85M.
What is Maravai LifeSciences Holdings, Inc. Price to Earnings Ratio (PE Ratio)?
Maravai LifeSciences Holdings, Inc. PE Ratio is now.
What was Maravai LifeSciences Holdings, Inc. earnings per share over the trailing 12 months (TTM)?
Maravai LifeSciences Holdings, Inc. EPS is -0.91 EUR over the trailing 12 months.
Which sector does the Maravai LifeSciences Holdings, Inc. company belong to?
The Maravai LifeSciences Holdings, Inc. sector is Healthcare.